Skip to main content
SpringerLink
Log in

Neuroendocrine Differentiation Patterns in Various Organs (Including Lung, Breast, Skin and Urogenital Tract)

  • Chapter
  • First Online:
Book cover Endocrine Pathology:

  • 2218 Accesses

Abstract

Tumors with pure or incomplete neuroendocrine phenotype may arise everywhere in the human body, including non-neuroendocrine organs, and share several common ultrastructural, morphological and phenoptypical properties; however, they do not constitute a single, uniform entity, but rather represent a spectrum of lesions in which the degree of neuroendocrine differentiation matches the clinical behavior. This chapter reviews the common diagnostic and classification criteria of these tumors in the lung, breast, skin and urogenital tract, and reports the molecular data that have been related to morphology in order to better understand their histogenesis and biological properties, as well as to identify novel therapeutic targets.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. DeLellis RA, Dayal Y (1997) Neuroendocrine system. In: Sternberg SS (ed) Histology for pathologists, 2nd edn. Lippincott-Raven Publishers, Philadelphia, pp 1133–1151

    Google Scholar 

  2. Bussolati G, Volante M, Papotti M (2001) Classic and recent special stains used in differential diagnosis of endocrine tumors. Endocr Pathol 12:379–387

    Article  CAS  PubMed  Google Scholar 

  3. Lovisetti-Scamihorn P, Fischer-Colbrie R, Leitner B, Scherzer G, Winkler H (1999) Relative amounts and molecular forms of NESP55 in various bovine tissues. Brain Res 829:99–106

    Article  CAS  PubMed  Google Scholar 

  4. Gould VE, Linnoila RI, Memoli VA, Warren WH (1983) Neuroendocrine components of the bronchopulmonary tract: hyperplasias, dysplasias, and neoplasms. Lab Invest 49:519–537

    CAS  PubMed  Google Scholar 

  5. Volante M, Fulcheri E, Allia E, Cerrato M, Pucci A, Papotti M (2002) Ghrelin expression in fetal, infant, and adult human lung. J Histochem Cytochem 50:1013–1021

    CAS  PubMed  Google Scholar 

  6. Sunday ME, Kaplan LM, Motoyama E, Chin WW, Spindel ER (1988) Gastrin-releasing peptide (mammalian bombesin) gene expression in health and disease. Lab Invest 59:5–24

    CAS  PubMed  Google Scholar 

  7. Pilmane M, Luts A, Sundler F (1995) Changes in neuroendocrine elements in bronchial mucosa in chronic lung disease in adults. Thorax 50:551–554

    Article  CAS  PubMed  Google Scholar 

  8. Aguayo SM, King TE Jr, Waldron JA Jr, Sherritt KM, Kane MA, Miller YE (1990) Increased pulmonary neuroendocrine cells with bombesin-like immunoreactivity in adult patients with eosinophilic granuloma. J Clin Invest 86:838–844

    Article  CAS  PubMed  Google Scholar 

  9. Gillan JE, Cutz E (1993) Abnormal pulmonary bombesin immunoreactive cells in Wilson-Mikity syndrome (pulmonary dysmaturity) and bronchopulmonary dysplasia. Pediatr Pathol 13:165–180

    Article  CAS  PubMed  Google Scholar 

  10. Miller RR, Muller NL (1995) Neuroendocrine cell hyperplasia and obliterative bronchiolitis in patients with peripheral carcinoid tumors. Am J Surg Pathol 19:653–658

    Article  CAS  PubMed  Google Scholar 

  11. Righi L, Volante M, Rapa I, Scagliotti GV, Papotti M (2007) Neuro-endocrine tumours of the lung. A review of relevant pathological and molecular data. Virchows Arch 451(Suppl 1):S51–S59

    Article  PubMed  Google Scholar 

  12. Travis WD, Gal AA, Colby TV, Klimstra DS, Falk R, Koss MN (1998) Reproducibility of neuroendocrine lung tumor classification. Hum Pathol 29:272–279

    Article  CAS  PubMed  Google Scholar 

  13. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC (eds) (2004) World Health Organization classification of tumours – pathology and genetics of tumours of the lung, pleura, thymus and heart. IARC Press, Lyon

    Google Scholar 

  14. Skov BG, Krasnik M, Lantuejoul S, Skov T, Brambilla E (2008) Reclassification of neuroendocrine tumors improves the separation of carcinoids and the prediction of survival. J Thorac Oncol 3:1410–1415

    Article  PubMed  Google Scholar 

  15. Gustafsson BI, Kidd M, Chan A, Malfertheiner MV, Modlin IM (2008) Bronchopulmonary neuroendocrine tumors. Cancer 113:5–21

    Article  CAS  PubMed  Google Scholar 

  16. Vageli D, Daniil Z, Dahabreh J, Karagianni E, Liloglou T, Koukoulis G, Gourgoulianis K (2006) Microsatellite instability and loss of heterozygosity at the MEN1 locus in lung carcinoid tumors: a novel approach using real-time PCR with melting curve analysis in histopathologic material. Oncol Rep 15:557–564

    CAS  PubMed  Google Scholar 

  17. Oliveira AM, Tazelaar HD, Wentzlaff KA, Kosugi NS, Hai N, Benson A, Miller DL, Yang P (2001) Familial pulmonary carcinoid tumors. Cancer 91:2104–2109

    Article  CAS  PubMed  Google Scholar 

  18. Takeuchi T, Minami Y, Iijima T, Kameya T, Asamura H, Noguchi M (2006) Characteristics of loss of heterozygosity in large cell neuroendocrine carcinomas of the lung and small cell lung carcinomas. Pathol Int 56:434–439

    Article  CAS  PubMed  Google Scholar 

  19. Onuki N, Wistuba II, Travis WD, Virmani AK, Yashima K, Brambilla E, Hasleton P, Gazdar AF (1999) Genetic changes in the spectrum of neuroendocrine lung tumors. Cancer 85:600–607

    Article  CAS  PubMed  Google Scholar 

  20. Kaye FJ (2002) RB and cyclin dependent kinase pathways: defining a distinction between RB and p16 loss in lung cancer. Oncogene 21:6908–6914

    Article  CAS  PubMed  Google Scholar 

  21. Yokomizo A, Tindall DJ, Drabkin H, Gemmill R, Franklin W, Yang P, Sugio K, Smith DI, Liu W (1998) PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers. Oncogene 17:475–479

    Article  CAS  PubMed  Google Scholar 

  22. Igarashi T, Jiang SX, Kameya T, Asamura H, Sato Y, Nagai K, Okayasu I (2004) Divergent cyclin B1 expression and Rb/p16/cyclin D1 pathway aberrations among pulmonary neuroendocrine tumors. Mod Pathol 17:1259–1267

    Article  CAS  PubMed  Google Scholar 

  23. Salon C, Merdzhanova G, Brambilla C, Brambilla E, Gazzeri S, Eymin B (2007) E2F-1, Skp2 and cyclin E oncoproteins are upregulated and directly correlated in high-grade neuroendocrine lung tumors. Oncogene 26:6927–6936

    Article  CAS  PubMed  Google Scholar 

  24. Marchetti A, Felicioni L, Pelosi G, Del Grammastro M, Fumagalli C, Sciarrotta M, Malatesta S, Chella A, Barassi F, Mucilli F, Camplese P, D’Antuono T, Sacco R, Buttitta F (2008) Frequent mutations in the neurotrophic tyrosine receptor kinase gene family in large cell neuroendocrine carcinoma of the lung. Hum Mutat 29:609–616

    Article  CAS  PubMed  Google Scholar 

  25. Anbazhagan R, Tihan T, Bornman DM, Johnston JC, Saltz JH, Weigering A, Piantadosi S, Gabrielson E (1999) Classification of small cell lung cancer and pulmonary carcinoid by gene expression profiles. Cancer Res 59:5119–5122

    CAS  PubMed  Google Scholar 

  26. Jones MH, Virtanen C, Honjoh D, Miyoshi T, Satoh Y, Okumura S, Nakagawa K, Nomura H, Ishikawa Y (2004) Two prognostically significant subtypes of high-grade lung neuroendocrine tumors independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles. Lancet 363:775–781

    Article  CAS  PubMed  Google Scholar 

  27. Pelosi G, Volante M, Papotti M, Sonzogni A, Masullo M, Viale G (2006) Peptide receptors in neuroendocrine tumors of the lung as potential tools for radionuclide diagnosis and therapy. Q J Nucl Med Mol Imaging 50:272–287

    CAS  PubMed  Google Scholar 

  28. Ceppi P, Volante M, Ferrero A, Righi L, Rapa I, Rosas R, Berruti A, Dogliotti L, Scagliotti GV, Papotti M (2008) Thymidylate synthase expression in gastroenteropancreatic and pulmonary neuroendocrine tumors. Clin Cancer Res 14:1059–1064

    Article  CAS  PubMed  Google Scholar 

  29. Tsurutani J, West KA, Sayyah J, Gills JJ, Dennis PA (2005) Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. Cancer Res 65:8423–8432

    Article  CAS  PubMed  Google Scholar 

  30. Bussolati G, Gugliotta P, Sapino A, Eusebi V, Lloyd RV (1985) Chromogranin-reactive endocrine cells in argyrophilic carcinomas (“carcinoids”) and normal tissue of the breast. Am J Pathol 20:186–192

    Google Scholar 

  31. Feyrter F, Hartmann G (1963) Über die carcinoide Wuchsform des Carcinoma mammae, insbesondere des Carcinoma solidum (gelatinosum) mammae. Frankfurter Zeitschrift für Pathologie 73:24–39

    CAS  PubMed  Google Scholar 

  32. Sapino A, Righi L, Cassoni P, Papotti M, Pietribiasi F, Bussolati G (2000) Expression of the NE phenotype in carcinomas of the breast. Sem Diagn Pathol 17:127–137

    CAS  Google Scholar 

  33. Tavassoli FA, Devilee P (2003) World Health Organization classification of tumours, pathology and genetics – tumours of the breast. IARC Press, Lyon

    Google Scholar 

  34. Sapino A, Righi L, Cassoni P, Papotti M, Gugliotta P, Bussolati G (2001) Expression of apocrine differentiation markers in NE breast carcinomas of aged women. Mod Pathol 14:768–776

    Article  CAS  PubMed  Google Scholar 

  35. Sapino A, Papotti M, Pietribiasi F, Bussolati G (1998) Diagnostic cytological feature of NE differentiated carcinoma of the breast. Virchows Arch 433:217–222

    Article  CAS  PubMed  Google Scholar 

  36. Kawasaki T, Nakamura S, Sakamoto G, Murata S, Tsunoda-Shimizu H, Suzuki K, Takahashi O, Nakazawa T, Kondo T, Katoh R (2008) Neuroendocrine ductal carcinoma in situ (NE-DCIS) of the breast – comparative clinicopathological study of 20 NE-DCIS cases and 274 non-NE-DCIS cases. Histopathology 53:288–298

    Article  CAS  PubMed  Google Scholar 

  37. Maluf HM, Koerner FC (1994) Carcinomas of the breast with endocrine differentiation: a riview. Virchows Archiv 425:449–457

    Article  CAS  PubMed  Google Scholar 

  38. Maluf HM, Koerner FC (1995) Solid papillary carcinoma of the breast a form of intraductal carcinoma with endocrine differentiation frequently associated with mucinous carcinoma. Am J Surg Pathol 19:1237–1244

    Article  CAS  PubMed  Google Scholar 

  39. Papotti M, Sapino A, Righi L, Chiappone S, Bussolati G (2001) 34betaE12 cytokeratin immunodetection in the differential diagnosis of NE carcinomas of the breast. Appl Immunohistochem Mol Morphol 9:229–233

    Article  CAS  PubMed  Google Scholar 

  40. Sapino A, Papotti M, Righi L, Cassoni P, Chiusa L, Bussolati G (2001) Clinical significance of NE carcinoma of the breast. Ann Oncol 12:115–117

    Article  Google Scholar 

  41. van Krimpen C, Elferink A, Broodman CA, Hop WC, Pronk A, Menke M (2004) The prognostic influence of neuroendocrine differentiation in breast cancer: results of a long-term follow-up study. Breast 13:329–333

    Article  PubMed  Google Scholar 

  42. Merkel F (1875) Tastzellen und Tastkorperchen bei den Haustieren und beim Menshen. Arch Mikrosk Anat 11:636

    Article  Google Scholar 

  43. Gould VE, Moll R, Moll I, Lee I, Franke WW (1985) Neuroendocrine (Merkel) cells of the skin: hyperplasias, dysplasias, and neoplasms. Lab Invest 52:334–353

    CAS  PubMed  Google Scholar 

  44. Toker C (1972) Trabecular carcinoma of the skin. Arch Dermatol 105:107–110

    Article  CAS  PubMed  Google Scholar 

  45. Heath M, Jaimes N, Lemos B, Mostaghimi A, Wang LC, Peñas PF, Nghiem P (2008) Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features. J Am Acad Dermatol 58:375–381

    Article  PubMed  Google Scholar 

  46. Andea AA, Coit DG, Amin B, Busam KJ (2008) Merkel cell carcinoma: histologic features and prognosis. Cancer 113:2549–2558

    Article  PubMed  Google Scholar 

  47. Foschini MP, Eusebi V (2000) Divergent differentiation in endocrine and nonendocrine tumors of the skin. Semin Diagn Pathol 17:162–168

    CAS  PubMed  Google Scholar 

  48. Pitale M, Sessions RB, Husain S (1992) An analysis of prognostic factors in cutaneous neuroendocrine carcinoma. Laryngoscope 102:244–249

    Article  CAS  PubMed  Google Scholar 

  49. Kim J, McNiff JM (2008) Nuclear expression of survivin portends a poor prognosis in Merkel cell carcinoma. Mod Pathol 21:764–769

    Article  CAS  PubMed  Google Scholar 

  50. Asioli S, Righi A, Volante M, Eusebi V, Bussolati G (2007) p63 expression as a new prognostic marker in Merkel cell carcinoma. Cancer 110:640–647

    Article  PubMed  Google Scholar 

  51. di Bartolomeo M, Bajetta E, Buzzoni R, Mariani L, Carnaghi C, Somma L, Zilembo N, di Leo A (1996) Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer 77:402–408

    Article  PubMed  Google Scholar 

  52. Papotti M, Macri L, Pagani A, Aloi F, Bussolati G (1999) Quantitation of somatostatin receptor type 2 in NE (Merkel cell) carcinoma of the skin by competitive RT-PCR. Endocr Pathol 10:37–46

    Article  Google Scholar 

  53. Guitera-Rovel P, Lumbroso J, Gautier-Gougis MS, Spatz A, Mercier S, Margulis A, Mamelle G, Kolb F, Lartigau E, Avril MF (2001) Indium-111 octreotide scintigraphy of Merkel cell carcinomas and their metastases. Ann Oncol 12:807–811

    Article  CAS  PubMed  Google Scholar 

  54. Chan JK, Suster S, Wenig BM, Tsang WY, Chan JB, Lau AL (1997) Cytokeratin 20 immunoreactivity distinguishes Merkel cell (primary cutaneous neuroendocrine) carcinomas and salivary gland small cell carcinomas from small cell carcinomas of various sites. Am J Surg Pathol 21:226–234

    Article  CAS  PubMed  Google Scholar 

  55. Byrd-Gloster AL, Khoor A, Glass LF, Messina JL, Whitsett JA, Livingston SK, Cagle PT (2000) Differential expression of thyroid transcription factor 1 in small cell lung carcinoma and Merkel cell tumor. Hum Pathol 31:58–62

    Article  CAS  PubMed  Google Scholar 

  56. Ralston J, Chiriboga L, Nonaka D (2008) MASH1: a useful marker in differentiating pulmonary small cell carcinoma from Merkel cell carcinoma. Mod Pathol 21:1357–1362

    Article  CAS  PubMed  Google Scholar 

  57. Van Gele M, Leonard JH, Van Roy N, Van Limbergen H, Van Belle S, Cocquyt V, Salwen H, De Paepe A, Speleman F (2002) Combined karyotyping. CGH and M-FISH analysis allows detailed characterization of unidentified chromosomal rearrangements in Merkel cell carcinoma. Int J Cancer 101:137–145

    Article  PubMed  Google Scholar 

  58. Paulson KG, Lemos BD, Feng B, Jaimes N, Peñas PF, Bi X, Maher E, Cohen L, Leonard JH, Granter SR, Chin L, Nghiem P (2009) Array-CGH reveals recurrent genomic changes in Merkel cell carcinoma including amplification of L-Myc. J Invest Dermatol 129(6):1547–1555

    Article  CAS  PubMed  Google Scholar 

  59. Brunner M, Thurnher D, Pammer J, Geleff S, Heiduschka G, Reinisch CM, Petzelbauer P, Erovic BM (2008) Expression of VEGF-A/C, VEGF-R2, PDGF-alpha/beta, c-kit, EGFR, Her-2/Neu, Mcl-1 and Bmi-1 in Merkel cell carcinoma. Mod Pathol 21:876–884

    Article  CAS  PubMed  Google Scholar 

  60. Kartha RV, Sundram UN (2008) Silent mutations in KIT and PDGFRA and coexpression of receptors with SCF and PDGFA in Merkel cell carcinoma: implications for tyrosine kinase-based tumorigenesis. Mod Pathol 21:96–104

    CAS  PubMed  Google Scholar 

  61. Feng H, Shuda M, Chang Y, Moore PS (2008) Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 319:1096–1100

    Article  CAS  PubMed  Google Scholar 

  62. Kassem A, Schöpflin A, Diaz C, Weyers W, Stickeler E, Werner M, Zur Hausen A (2008) Frequent detection of Merkel cell polyomavirus in human Merkel cell carcinomas and identification of a unique deletion in the VP1 gene. Cancer Res 68:5009–5013

    Article  CAS  PubMed  Google Scholar 

  63. Eloy-Garcia Carrasco C, Benguigui Benadiva J, Martinez Garcia S, Sanz Trelles A, Palacios S (2006) Atypical primary carcinoid tumour of the skin. J Cutan Pathol 33(Suppl 2):32–34

    Article  PubMed  Google Scholar 

  64. Eusebi V, Mambelli V, Tison V, De Lellis R, Betts CM (1979) Endocrine differentiation in basal cell carcinoma. Tumori 65:191–199

    CAS  PubMed  Google Scholar 

  65. George E, Swanson PE, Wick MR (1989) Neuroendocrine differentiation in basal cell carcinoma. An immunohistochemical study. Am J Dermatopathol 11:131–135

    Article  CAS  PubMed  Google Scholar 

  66. Collina G, Macri L, Eusebi V (2001) Endocrine differentiation in basocellular carcinoma. Pathologica 93:208–212

    CAS  PubMed  Google Scholar 

  67. Hartschuh W, Schulz T (1999) Immunohistochemical investigation of the different developmental stages of trichofolliculoma with special reference to the Merkel cell. Am J Dermatopathol 21:8–15

    Article  CAS  PubMed  Google Scholar 

  68. Abrahamsson PA, Wadstrom LB, Alumets J, Falkmer S, Grimelius L (1986) Peptide-hormone- and serotonin-immunoreactive cells in normal and hyperplastic prostate glands. Pathol Res Pract 181:675–683

    CAS  PubMed  Google Scholar 

  69. Schmid KW, Helpap B, Totsch M, Kirchmair R, Dockhorn-Dworniczak B, Bocker W, Fischer-Colbrie R (1994) Immunohistochemical localization of chromogranins A and B and secretogranin II in normal, hyperplastic and neoplastic prostate. Histopathology 24:233–239

    Article  CAS  PubMed  Google Scholar 

  70. di Sant’Agnese PA (1986) Calcitonin-like immunoreactive and bombesin-like immunoreactive endocrine-paracrine cells of the human prostate. Arch Pathol Lab Med 110:412–415

    PubMed  Google Scholar 

  71. di Sant’Agnese PA, de Mesy Jensen KL (1984) Somatostatin and/or somatostatin-like immunoreactive endocrine-paracrine cells in the human prostate gland. Arch Pathol Lab Med 108:693–696

    PubMed  Google Scholar 

  72. Iwamura M, Wu G, Abrahamsson PA, di Sant’Agnese PA, Cockett AT, Deftos LJ (1994) Parathyroid hormone-related protein is expressed by prostatic neuroendocrine cells. Urology 43:667–674

    Article  CAS  PubMed  Google Scholar 

  73. Bonkhoff H, Stein U, Remberger K (1993) Androgen receptor status in endocrine-paracrine cell types of the normal, hyperplastic, and neoplastic human prostate. Virchows Arch A Pathol Anat Histopathol 423:291–294

    Article  CAS  PubMed  Google Scholar 

  74. Santamaria L, Martin R, Martin JJ, Alonso L (2002) Stereologic estimation of the number of neuroendocrine cells in normal human prostate detected by immunohistochemistry. Appl Immunohistochem Mol Morphol 10:275–281

    Article  CAS  PubMed  Google Scholar 

  75. Feirter F (1938) Uber diffuse dokrine epithaliale organe. Barth, Leipzig, Germany

    Google Scholar 

  76. Fetissof F, Dubois MP, Arbeille-Brassart B, Lanson Y, Boivin F, Jobard P (1983) Endocrine cells in the prostate gland, urothelium and Brenner tumors. Immunohistological and ultrastructural studies. Virchows Arch B Cell Pathol Incl Mol Pathol 42:53–64

    CAS  PubMed  Google Scholar 

  77. Murali R, Kneale K, Lalak N, Delprado W (2006) Carcinoid tumors of the urinary tract and prostate. Arch Pathol Lab Med 130:1693–1706

    PubMed  Google Scholar 

  78. Ghali VS, Garcia RL (1984) Prostatic adenocarcinoma with carcinoidal features producing adrenocorticotropic syndrome. Immunohistochemical study and review of the literature. Cancer 54:1043–1048

    Article  CAS  PubMed  Google Scholar 

  79. Cramer SF, Aikawa M, Cebelin M (1981) Neurosecretory granules in small cell invasive carcinoma of the urinary bladder. Cancer 47:724–730

    Article  CAS  PubMed  Google Scholar 

  80. Stein ME, Bernstein Z, Abacioglu U, Sengoz M, Miller RC, Meirovitz A, Zouhair A, Freixa SV, Poortmans PH, Ash R, Kuten A (2008) Small cell (neuroendocrine) carcinoma of the prostate: etiology, diagnosis, prognosis, and therapeutic implications – a retrospective study of 30 patients from the rare cancer network. Am J Med Sci 336:478–488

    Article  PubMed  Google Scholar 

  81. Evans AJ, Humphrey PA, Belani J, van der Kwast TH, Srigley JR (2006) Large cell neuroendocrine carcinoma of prostate: a clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancer. Am J Surg Pathol 30:684–693

    Article  PubMed  Google Scholar 

  82. Alijo Serrano F, Sánchez-Mora N, Angel Arranz J, Hernández C, Alvarez-Fernández E (2007) Large cell and small cell neuroendocrine bladder carcinoma: immunohistochemical and outcome study in a single institution. Am J Clin Pathol 128:733–739

    Article  PubMed  Google Scholar 

  83. Oesterling JE, Brendler CB, Burgers JK, Marshall FF, Epstein JI (1990) Advanced small cell carcinoma of the bladder. Successful treatment with combined radical cystoprostatectomy and adjuvant methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy. Cancer 65:1928–1936

    Article  CAS  PubMed  Google Scholar 

  84. Helpap B, Kloppel G (2002) Neuroendocrine carcinomas of the prostate and urinary bladder: a diagnostic and therapeutic challenge. Virchows Arch 440:241–248

    Article  CAS  PubMed  Google Scholar 

  85. Adlakha H, Bostwick DG (1994) Paneth cell-like change in prostatic adenocarcinoma represents neuroendocrine differentiation: report of 30 cases. Hum Pathol 25:135–139

    Article  CAS  PubMed  Google Scholar 

  86. di Sant’Agnese PA (2001) Neuroendocrine differentiation in prostatic carcinoma: an update on recent developments. Ann Oncol 12(Suppl 2):S135–S140

    Article  PubMed  Google Scholar 

  87. Bonkhoff H (2001) Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status. Ann Oncol 12(Suppl 2):S141–S144

    Article  PubMed  Google Scholar 

  88. Mazzucchelli R, Montironi R, Santinelli A, Lucarini G, Pugnaloni A, Bigini G (2000) Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients. Prostate 45:72–79

    Article  CAS  PubMed  Google Scholar 

  89. Xing N, Qian J, Bostwick D, Bergstralh E, Young CY (2001) Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin. Prostate 48:7–15

    Article  CAS  PubMed  Google Scholar 

  90. Berruti A, Mosca A, Tucci M, Terrone C, Torta M, Tarabuzzi R, Russo L, Cracco C, Bollito E, Scarpa RM, Angeli A, Dogliotti L (2005) Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease. Endocr Relat Cancer 12:109–117

    Article  CAS  PubMed  Google Scholar 

  91. Taplin ME, George DJ, Halabi S, Sanford B, Febbo PG, Hennessy KT, Mihos CG, Vogelzang NJ, Small EJ, Kantoff PW (2005) Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study. Urology 66:386–391

    Article  PubMed  Google Scholar 

  92. Bollito E, Berruti A, Bellina M, Mosca A, Leonardo E, Tarabuzzi R, Cappia S, Ari MM, Tampellini M, Fontana D, Gubetta L, Angeli A, Dogliotti L (2001) Relationship between neuroendocrine features and prognostic parameters in human prostate adenocarcinoma. Ann Oncol 12(Suppl 2):S159–S164

    Article  PubMed  Google Scholar 

  93. Puccetti L, Supuran CT, Fasolo PP, Conti E, Sebastiani G, Lacquaniti S, Mandras R, Milazzo MG, Dogliani N, De Giuli P, Fasolis G (2005) Skewing towards neuroendocrine phenotype in high grade or high stage androgen-responsive primary prostate cancer. Eur Urol 48:215–221

    Article  PubMed  Google Scholar 

  94. Sharifi N, Gulley JL, Dahut WL (2005) Androgen deprivation therapy for prostate cancer. JAMA 294:238–244

    Article  CAS  PubMed  Google Scholar 

  95. Jongsma J, Oomen MH, Noordzij MA, Van Weerden WM, Martens GJ, van der Kwast TH, Schroder FH, van Steenbrugge GJ (2002) Different profiles of neuroendocrine cell differentiation evolve in the PC-310 human prostate cancer model during long-term androgen deprivation. Prostate 50:203–215

    Article  CAS  PubMed  Google Scholar 

  96. Sciarra A, Monti S, Gentile V, Mariotti G, Cardi A, Voria G, Lucera R, Di Silverio F (2003) Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma. Prostate 55:168–179

    Article  PubMed  Google Scholar 

  97. Rapa I, Ceppi P, Bollito E, Rosas R, Cappia S, Bacillo E, Porpiglia F, Berruti A, Papotti M, Volante M (2008) Human ASH1 expression in prostate cancer with neuroendocrine differentiation. Mod Pathol 21:700–707

    Article  CAS  PubMed  Google Scholar 

  98. Cheng L, Leibovich BC, Cheville JC, Ramnani DM, Sebo TJ, Neumann RM, Nascimento AG, Zincke H, Bostwick DG (2000) Paraganglioma of the urinary bladder: can biologic potential be predicted? Cancer 88:844–852

    Article  CAS  PubMed  Google Scholar 

  99. Shapiro B, Gonzalez E, Weissman A, McHugh T, Markel SF (1997) Malignant paraganglioma of the prostate: case report, depiction by meta-iodobenzylguanidine scintigraphy and review of the literature. Q J Nucl Med 41:36–41

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biomedical Sciences and Oncology, University of Turin, Medical School, Institute of Pathology, Via Santena 7, 10126, Turin, Italy

    Gianni Bussolati

Authors
  1. Marco Volante
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anna Sapino
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mauro Papotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Donatella Pacchioni
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gianni Bussolati
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gianni Bussolati .

Editor information

Editors and Affiliations

  1. Dept. Laboratory Medicine & Pathology, Mayo Clinic, First Street SW 200, Rochester, 55905, U.S.A.

    Ricardo V. Lloyd

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Volante, M., Sapino, A., Papotti, M., Pacchioni, D., Bussolati, G. (2010). Neuroendocrine Differentiation Patterns in Various Organs (Including Lung, Breast, Skin and Urogenital Tract). In: Lloyd, R. (eds) Endocrine Pathology:. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-1069-1_18

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-1069-1_18

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4419-1068-4

  • Online ISBN: 978-1-4419-1069-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation